Metal-proteinase ADAM12, kinesin 14 and checkpoint suppressor 1 as new molecular markers of laryngeal carcinoma.
The assessment of gene expression profile in laryngeal cancer allows implementation of molecular biology methods in diagnostics, as well as in prognosticating the course of disease, thus allowing taking most optimal decisions as regards the method of treatment, scope of surgical procedure, or the necessity of adding complementary radiotherapy. The aim of the project was to analyze the gene expression profile in laryngeal cancer using oligonucleotide microarrays, having in mind searching new molecular markers for that carcinoma. The study comprised a group of 43 patients (38 males and 5 females) suffering from squamous cell laryngeal carcinoma, diagnosed and surgically treated in the years 2005-2007 in the ENT Department of the Silesian Medical University in Katowice, Poland. RNA was isolated from frozen tissue fragments, with the use of columns RNeasy Midi and Mini Kit (Qiagen). For the examination of gene expression profile, oligonucleotide microarrays of high density were used, provided by Affymetrix (U 133 2.0 PLUS) containing over 54,000 probes for over 47,000 transcripts. Four genes previously not examined in that respect in laryngeal carcinoma, occurred to be good markers of the neoplasm. They are: metal-proteinase ADAM12, cyclin-dependent kinase 2-CDK2, kinesin 14-KIF14, suppressor 1 of checkpoint-CHES1. The analysis of gene expression profile allows, in laryngeal carcinoma, to point out to new genes, which in future may become molecular markers of the carcinoma.
Markowski
Jarosław
J
ENT Department, Silesian Medical University, Francuska Str. 20-24, 40-270, Katowice, Poland. jmarkow1@poczta.onet.pl
Tyszkiewicz
Tomasz
T
Jarzab
Michał
M
Oczko-Wojciechowska
Małgorzata
M
Gierek
Tatiana
T
Witkowska
Małgorzata
M
Paluch
Jarosław
J
Kowalska
Małgorzata
M
Wygoda
Zbigniew
Z
Lange
Dariusz
D
Jarzab
Barbara
B
D051722:ADAM Proteins / Q000235:genetics*; D000072199:ADAM12 Protein; D014408:Biomarkers, Tumor / Q000235:genetics*; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis / Q000235:genetics* / Q000473:pathology; D018797:Cell Cycle Proteins / Q000235:genetics*; D051357:Cyclin-Dependent Kinase 2 / Q000235:genetics*; D051858:Forkhead Transcription Factors; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics; D006801:Humans; D016547:Kinesins / Q000235:genetics*; D007820:Laryngeal Mucosa / Q000473:pathology; D007822:Laryngeal Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000473:pathology; D008565:Membrane Proteins / Q000235:genetics*; D020411:Oligonucleotide Array Sequence Analysis; D015513:Oncogene Proteins / Q000235:genetics*; D025341:Principal Component Analysis; D011379:Prognosis; D012016:Reference Values; D012097:Repressor Proteins / Q000235:genetics*
D014408:Biomarkers, Tumor; D018797:Cell Cycle Proteins; C106158:FOXN3 protein, human; D051858:Forkhead Transcription Factors; D008565:Membrane Proteins; D015513:Oncogene Proteins; D012097:Repressor Proteins; C495894:CDK2 protein, human; D051357:Cyclin-Dependent Kinase 2; D051722:ADAM Proteins; D000072199:ADAM12 Protein; C000606480:ADAM12 protein, human; C502598:KIF14 protein, human; D016547:Kinesins